June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Ranibizumab in a real-world clinical setting: 2014 interim analysis of the 5-year observational multicenter LUMINOUS study
Author Affiliations & Notes
  • Eric H Souied
    Ophthalmology (Retina), Hôpital Intercommunal de Creteil, University Paris Est Creteil, Creteil, France
  • Boris Gekkiev
    Novartis Pharma AG, Basel, Switzerland
  • Adrien Bretagne
    Novartis Pharma AG, Basel, Switzerland
  • Stefan Pilz
    Novartis Pharma AG, Basel, Switzerland
  • Sue Lacey
    Novartis Pharma AG, Basel, Switzerland
  • Footnotes
    Commercial Relationships Eric Souied, Allergan (C), Bausch+Lomb (C), Bayer (C), Novartis (C), Thea (C); Boris Gekkiev, Novartis (E), Novartis (E); Adrien Bretagne, Novartis (E); Stefan Pilz, Novartis (E); Sue Lacey, Novartis (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 1417. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Eric H Souied, Boris Gekkiev, Adrien Bretagne, Stefan Pilz, Sue Lacey, ; Ranibizumab in a real-world clinical setting: 2014 interim analysis of the 5-year observational multicenter LUMINOUS study. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1417.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

LUMINOUS (NCT01318941, initiated March 2011) is the largest prospective observational global study in the field of medical retina. The study is designed to evaluate the long-term safety, effectiveness, treatment patterns, and health-related quality-of-life associated with ranibizumab 0.5 mg treatment, across all approved indications, in 30,000 patients from routine clinical practice. We present data from the 2014 interim analysis.

 
Methods
 

This interim analysis included 3 cohorts: Cohort 1, baseline characteristics of patients enrolled before March 2014 (N=20,085; nAMD, n=17,546; DME, n=1,758; BRVO, n=393; CRVO, n=350); Cohort 2, patients with potential for 1-year follow-up enrolled before March 2013 (N=9790; nAMD, n=9125; DME, n=427; BRVO, n=119; CRVO, n=119); and Cohort 3, patients with potential for 2-year follow-up enrolled before March 2012 (nAMD, N=2001).

 
Results
 

Cohort 1: LUMINOUS included patients with diverse demographics and baseline characteristics (Table 1). Across all indications, mean baseline visual acuity (VA, ETDRS letters) was higher in patients previously treated with ranibizumab (56.5) than in treatment-naïve patients (49.3). Cohort 2: The 1-year data showed that on average treatment-naïve patients gained VA from baseline whilst those previously treated with ranibizumab either gained or maintained VA. These outcomes were obtained with a relatively low number of injections and visits (Table 2). In nAMD, VA was maintained at 1-year even in those patients who were previously treated with ranibizumab for ≥6 years. Cohort 3: At Year 2, there was a mean increase in VA of 2.0 ETDRS letters from a baseline VA of 54.9 ETDRS letters in treatment naïve patients whilst those previously treated with ranibizumab lost 3.0 ETDRS letters of VA from a higher baseline of 60.4 ETDRS letters. At Year 1 (Cohort 2) and Year 2 (Cohort 3), the rates of ocular and non-ocular serious adverse events were 0.54/0.70% and 6.52/13.34%, respectively.

 
Conclusions
 

This interim analysis of LUMINOUS study data reinforces the well-established efficacy and safety profile of ranibizumab in a real-world clinical setting. LUMINOUS will provide an invaluable source of long-term real-world data.  

 
Table 1. Baseline characteristics of patients enrolled before March 2014
 
Table 1. Baseline characteristics of patients enrolled before March 2014
 
 
Table 2. Outcomes at Year 1 and Year 2
 
Table 2. Outcomes at Year 1 and Year 2

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×